We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+9.84%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$15.7B
AUM Growth
+$958M
Cap. Flow
-$459M
Cap. Flow %
-2.93%
Top 10 Hldgs %
22.96%
Holding
925
New
41
Increased
262
Reduced
364
Closed
130

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$97.5M
2
PYPL icon
PayPal
PYPL
+$66.8M
3
HOLX
Hologic
HOLX
+$44.4M
4
BNTX icon
BioNTech
BNTX
+$35M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.3M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$80.5M
2
XLRN
Acceleron Pharma
XLRN
+$79.5M
3
AAPL icon
Apple
AAPL
+$55.8M
4
ONC
BeOne Medicines Ltd
ONC
+$44.9M
5
VZ icon
Verizon
VZ
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 31.29%
2 Technology 26.69%
3 Financials 8.86%
4 Communication Services 7.82%
5 Consumer Discretionary 7.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
301
TG Therapeutics
TGTX
$8.19B
$6.72M 0.04%
353,983
– –
BBIO icon
302
BridgeBio Pharma
BBIO
$16.4B
$6.7M 0.04%
401,912
-53,373
-12% -$2.26M
NOMD icon
303
Nomad Foods
NOMD
$1.77B
$6.65M 0.04%
261,925
+30,338
+13% +$783K
JKHY icon
304
Jack Henry & Associates
JKHY
$11.4B
$6.64M 0.04%
39,740
-261
-0.7% -$42.2K
MU icon
305
Micron Technology
MU
$835B
$6.63M 0.04%
71,157
-145,759
-67% -$11.4M
F icon
306
Ford
F
$60.9B
$6.61M 0.04%
318,089
-73,486
-19% -$1.35M
ACAD icon
307
Acadia Pharmaceuticals
ACAD
$4.51B
$6.43M 0.04%
275,560
– –
ETNB
308
DELISTED
89bio
ETNB
$6.38M 0.04%
488,197
– –
OKTA icon
309
Okta
OKTA
$23.8B
$6.32M 0.04%
28,206
+18,313
+185% +$4.36M
DNLI icon
310
Denali Therapeutics
DNLI
$3.79B
$6.31M 0.04%
141,507
+77,726
+122% +$3.68M
TSC
311
DELISTED
TriState Capital Holdings, Inc.
TSC
$6.27M 0.04%
+207,290
New +$5.85M
EME icon
312
Emcor
EME
$29.9B
$6.25M 0.04%
49,052
+8,930
+22% +$1.11M
ITCI
313
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.16M 0.04%
117,617
-367,849
-76% -$15.5M
BEAM icon
314
Beam Therapeutics
BEAM
$2.68B
$6.15M 0.04%
77,147
– –
CPRT icon
315
Copart
CPRT
$28.5B
$6.13M 0.04%
161,684
-4,380
-3% -$163K
YUM icon
316
Yum! Brands
YUM
$41.9B
$6.12M 0.04%
20,088
+4,160
+26% +$532K
HARP
317
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$6.11M 0.04%
80,957
+32,006
+65% +$2.18M
BAP icon
318
Credicorp
BAP
$30.5B
$6.05M 0.04%
+49,600
New +$6.08M
NSC icon
319
Norfolk Southern
NSC
$75.4B
$6.02M 0.04%
20,231
-41,259
-67% -$11.5M
COF icon
320
Capital One
COF
$128B
$6.01M 0.04%
41,396
-2,972
-7% -$459K
AMED
321
DELISTED
Amedisys
AMED
$5.95M 0.04%
+14,000
New +$2.25M
DCPH
322
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.91M 0.04%
604,379
-103,738
-15% -$1.95M
RIGL icon
323
Rigel Pharmaceuticals
RIGL
$723M
$5.89M 0.04%
222,170
– –
VEEV icon
324
Veeva Systems
VEEV
$33.8B
$5.83M 0.04%
22,808
+2,341
+11% +$681K
PAYX icon
325
Paychex
PAYX
$43.4B
$5.81M 0.04%
42,592
-7,572
-15% -$936K
11 12
13
14 15

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2021 Portfolio in Review

As of Q4 2021, Candriam SCA held 925 positions worth $15.7B, up 6.5% from $14.7B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Candriam SCA's Q4 2021 filing shows 41 new, 262 increased, 364 reduced and 130 closed positions. Its largest new stake was Couchbase: 858,038 shares worth $21.4M. The largest sale was Merck, an estimated $80.5M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2021 buy was Couchbase: 858,038 shares worth $21.4M.
  • Candriam SCA added most to Eli Lilly in Q4 2021, an estimated $97.5M increase.
  • Candriam SCA's biggest Q4 2021 reduction was Merck, cutting an estimated $80.5M.
  • Candriam SCA fully exited Acceleron Pharma in Q4 2021, selling an estimated $79.5M.
  • Candriam SCA's ten largest holdings make up 23% of its $15.7B portfolio in Q4 2021.
  • Candriam SCA opened 41 new positions and closed 130 in Q4 2021.
  • Candriam SCA's portfolio value rose 6.5% quarter-over-quarter to $15.7B.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.